Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript
Appointed director

Astex Pharmaceuticals, Inc (ASTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2013 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Astex Pharmaceuticals, Inc., effective as of October 11, 2013",
"Bylaws of Astex Pharmaceuticals, Inc., effective as of October 11, 2013"
09/05/2013 8-K Quarterly results
08/01/2013 8-K Quarterly results
Docs: "Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results"
04/29/2013 8-K Quarterly results
Docs: "Astex Pharmaceuticals Reports 2013 First Quarter Financial Results"
10/30/2012 8-K Quarterly results
Docs: "Astex Pharmaceuticals Reports 2012 Third Quarter Financial Results"
09/28/2012 8-K Other Events, Financial Statements and Exhibits
07/30/2012 8-K Form 8-K - Current report
06/28/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Contract of Employment effective June 22, 2012 by and between Astex Therapeutics Limited and Dr. Harren Jhoti",
"Confidentiality and Proprietary Information Deed effective June 22, 2012 by and between Astex Pharmaceuticals, Inc., Astex Therapeutics Limited, and Dr. Harren Jhoti",
"Contract of Employment effective June 22, 2012 by and between Astex Therapeutics Limited and Martin Buckland",
"Confidentiality and Proprietary Information Deed effective June 22, 2012 by and between Astex Pharmaceuticals, Inc., Astex Therapeutics Limited, and Martin Buckland",
"Severance Benefit Plan for Officers effective June 22, 2012"
06/25/2012 8-K Submission of Matters to a Vote of Security Holders
04/30/2012 8-K Quarterly results
Docs: "Astex Pharmaceuticals Reports 2012 First Quarter Financial Results"
03/13/2012 8-K Form 8-K - Current report
03/05/2012 8-K Form 8-K - Current report
01/20/2012 8-K Form 8-K - Current report
10/31/2011 8-K Form 8-K - Current report
09/30/2011 8-K/A Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
08/03/2011 8-K Form 8-K - Current report
07/20/2011 8-K Appointed a new director
Docs: "SuperGen Completes Acquisition of Astex Therapeutics DUBLIN, Calif., July 20, 2011 — SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it has closed the transaction to acquire Astex Therapeutics Limited , a privately held, UK-based biotechnology company developing targeted therapies. Today, Astex Therapeutics Limited became a wholly owned subsidiary of SuperGen, Inc. SuperGen purchased all outstanding shares of Astex for approximately $25 million in cash and 32.4 million shares of SuperGen common stock representing 35 percent of the total post closing shares outstanding. In addition, SuperGen will pay deferred consideration in the amount of $30 million in either stock or cash, at the discretion of the combined entity, ...",
"Employment Agreement between Astex Technology Limited and Harren Jhoti (Astex Technology Limited changed its name to Astex Therapeutics Limited on June 27, 2005)",
"Employment Agreement between Astex Technology Limited and Martin Buckland (Astex Technology Limited changed its name to Astex Therapeutics Limited on June 27, 2005)"
06/16/2011 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "SuperGen Stockholders Approve Stock Issuance In Connection with the Proposed Acquisition of Astex Therapeutics Limited DUBLIN, Calif., June 16, 2011 — SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that stockholders have approved the issuance of shares to be issued in connection with the proposed acquisition of Astex Therapeutics Limited , a privately held, U.K.-based biotechnology company developing targeted therapies. The proposal to approve the share issuances in connection with the proposed acquisition of Astex passed by those voting either in person or by proxy at SuperGen's annual meeting of stockholders on June 16, 2011. On June 13, 2011, the shareholders of Astex voted to approve the transaction. “We are ver..."
04/27/2011 8-K Form 8-K - Current report
04/06/2011 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Implementation Agreement, between SuperGen, Inc., and Astex Therapeutics Limited, a UK corporation, (certain schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K and will be provided to the Securities and Exchange Commission upon request)",
"Form of Support Agreement among Astex Therapeutics Limited, a UK corporation, and certain stockholders of SuperGen, Inc",
"SUPERGEN AND ASTEX THERAPEUTICS ENTER DEFINITIVE MERGER AGREEMENT"
03/28/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/18/2011 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Bylaws of SuperGen, Inc. (as amended and restated through March 17, 2011)",
"Bylaws of SuperGen, Inc. (as amended and restated through March 17, 2011)"
03/11/2011 8-K Form 8-K - Current report
02/28/2011 8-K Quarterly results
Docs: "SuperGen Reports 2010 Fourth Quarter and Year-End Financial Results Reports Annual Net Income of $16.3 Million Dacogen Royalty Revenue Increases 27% from the Prior Year Ends Year with Over $120 million in Cash & Marketable Securities"
10/25/2010 8-K Form 8-K - Current report
10/04/2010 8-K Form 8-K - Current report
08/06/2010 8-K Form 8-K - Current report
08/02/2010 8-K Quarterly results
Docs: "SuperGen Reports 2010 Second Quarter Financial Results"
06/14/2010 8-K Submission of Matters to a Vote of Security Holders
04/26/2010 8-K Quarterly results
Docs: "SuperGen Reports 2010 First Quarter Financial Results"
03/19/2010 8-K Form 8-K - Current report
03/01/2010 8-K Quarterly results
Docs: "SuperGen Reports 2009 Fourth Quarter and Year-End Financial Results Achieves net income for quarter & year of $2.3 million and $4.7 million, respectively Ends year with over $100 million in cash, cash equivalents & marketable securities"
01/22/2010 8-K Form 8-K - Current report
10/28/2009 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy